8-K: Cypherpunk Technologies Secures $200M ATM Equity Offering

Cypherpunk Technologies Inc., formerly Leap Therapeutics, has entered into an agreement with Cantor Fitzgerald & Co. to sell up to $200 million of its common stock through an 'at-the-market' offering.

Summary

• The company, formerly known as Leap Therapeutics, Inc., officially changed its name to Cypherpunk Technologies Inc. effective November 12, 2025.
• Cypherpunk Technologies Inc. entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. on November 12, 2025.
• Under this agreement, the company may offer and sell shares of its common stock with an aggregate offering price of up to $200,000,000.
• Cantor Fitzgerald & Co. will act as principal and/or sales agent, using commercially reasonable efforts to sell the shares.
• Sales of shares, if any, will be made in transactions deemed 'at-the-market offerings' as defined in Rule 415 under the Securities Act of 1933.
• The company has no obligation to sell any shares and may suspend offers at any time.
• Cantor Fitzgerald & Co. will receive a commission of up to 3.0% of the gross proceeds from each sale of shares.
• The offering is being made pursuant to the company's shelf registration statement on Form S-3 (File No. 333-278015), which was declared effective on May 9, 2024.

Sentiment

Score: 6

Explanation: The filing indicates a proactive step to secure future funding, which is generally positive for financial stability and strategic flexibility. However, the potential for shareholder dilution and the lack of immediate, guaranteed capital raise temper the overall sentiment. The pivot to 'Cypherpunk Technologies' and crypto assets is a significant strategic shift that introduces both opportunity and new risks, making a neutral-to-slightly positive score appropriate without further context on the new business direction.

Positives

• Provides access to up to $200,000,000 in capital, enhancing financial flexibility for general corporate purposes, working capital, or strategic initiatives.
• The 'at-the-market' offering structure allows for opportunistic and flexible capital raises, potentially minimizing market disruption compared to traditional underwritten offerings.
• The company retains discretion to control the timing, price, and volume of share sales, aligning capital raises with market conditions and funding needs.

Negatives

• Potential for dilution of existing shareholders due to the issuance of new common stock.
• The 3.0% commission payable to Cantor Fitzgerald & Co. will reduce the net proceeds received by the company from sales.
• There is no assurance that the Agent will be successful in selling Placement Shares, meaning the capital raise is not guaranteed.

Risks

• Market price fluctuations could significantly impact the amount of capital raised and the timing of sales under the agreement.
• The potential for dilution of existing shareholders is a risk if a substantial number of shares are sold through the offering.
• The company has no obligation to sell shares, and the Agent is not obligated to purchase shares on a principal basis, meaning the capital raise is not assured.
• Either the company or the Agent may terminate the Sales Agreement upon ten business days' notice, which could halt capital raising efforts.
• The Agent may terminate the agreement under various adverse market conditions (e.g., material adverse change, trading suspension, banking moratorium), potentially preventing the company from raising capital when needed.
• Ongoing compliance with various regulatory requirements (Securities Act, Exchange Act, FINRA, Nasdaq) is necessary, and any failure could adversely impact the offering.
• The company's ability to raise capital is contingent on the continued effectiveness of its Registration Statement and adherence to all applicable laws and listing requirements.
• The company's pivot to 'Cypherpunk Technologies' and focus on 'Crypto Assets' introduces new business and regulatory risks inherent to the evolving cryptocurrency and blockchain sector.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, capital expenditures, and other strategic initiatives. The 'at-the-market' structure provides ongoing flexibility to raise capital as needed to support future operations and growth.

Management Comments

• Cypherpunk Technologies Inc. (f./k./a Leap Therapeutics, Inc.) entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co.
• The company has no obligation to sell any of the shares and may at any time suspend offers under the Sales Agreement.

Industry Context

The company's name change from 'Leap Therapeutics, Inc.' to 'Cypherpunk Technologies Inc.' and the explicit mention of 'Crypto Assets' and 'Zcash (ZEC)' in the filing's representations indicate a significant strategic pivot or expansion into the cryptocurrency and blockchain technology sector. This 'at-the-market' offering provides a flexible capital-raising mechanism to support this new strategic direction or ongoing operations in the evolving tech/crypto space, a common financing tool for companies seeking growth capital in dynamic industries.

Comparison to Industry Standards

• The 'at-the-market' (ATM) offering structure is a widely adopted and flexible capital-raising tool for publicly traded companies, particularly those in growth-oriented sectors like technology or biotechnology, enabling efficient access to public markets without the complexities of a traditional underwritten offering.
• The commission rate of up to 3.0% for the sales agent is consistent with typical industry ranges for ATM offerings, which can vary based on market conditions, company size, and trading liquidity.
• The maximum offering size of $200 million represents a substantial potential capital infusion, comparable to offerings seen from mid-to-large cap companies seeking to fund research and development, mergers and acquisitions, or general corporate purposes.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from the issuance of new common stock, but also benefits from enhanced financial flexibility for the company.
• Investors: Provides an opportunity to invest in the company's common stock through an 'at-the-market' mechanism.
• Company: Gains a flexible mechanism to raise capital for general corporate purposes, working capital, or strategic initiatives, particularly in light of its new strategic direction.

Next Steps

• The company may issue Placement Notices to Cantor Fitzgerald & Co. to initiate sales of common stock.
• Cantor Fitzgerald & Co. will use commercially reasonable efforts to sell shares based on the company's instructions.
• The company will disclose the number of shares sold and net proceeds in future Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
• The company will continue to comply with SEC reporting and Nasdaq listing requirements.

Key Dates

Recommendation

The announcement of a $200 million 'at-the-market' equity offering provides Cypherpunk Technologies Inc. with significant financial flexibility to fund its operations and strategic initiatives. However, the potential for shareholder dilution from future share sales is a consideration. The company's recent name change from Leap Therapeutics, Inc. to Cypherpunk Technologies Inc., coupled with explicit mentions of 'Crypto Assets' and 'Zcash (ZEC)' in the filing's representations, signals a substantial strategic pivot towards the cryptocurrency and blockchain technology sector. While this pivot could unlock new growth opportunities, it also introduces new risks and requires careful evaluation of the company's execution capabilities in this new domain. Given the balance of potential capital infusion, dilution risk, and a significant strategic shift, a 'hold' recommendation is appropriate for investors to observe the company's progress and the market's reaction to its new direction before making further investment decisions.

Keywords

Cypherpunk Technologies, Leap Therapeutics, ATM Offering, At-The-Market, Equity Offering, Capital Raise, Common Stock, Nasdaq, Cantor Fitzgerald, Form S-3, Dilution, Crypto Assets, Zcash